Glaxo Lacks Diversified Drug Portfolio: Rundquist

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

July 24 (Bloomberg) -- Odile Rundquist, senior analyst at Helvea, previews quarterly results from Glaxo Smithkline, looks at the impact of the drugmaker's recent troubles in China and compares the U.S. and European pharma sectors. She speaks on Bloomberg Television's "On The Move."

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change